InflaRx N.V. (IFRX)
NASDAQ: IFRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IFRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $153.26M
- EPS (TTM)
- -$0.37
- Dividend yield
- None
- 52-week range
- 0.798 – 2.95
- Day range
- 1.03 – 1.12
- Volume / Avg
- 472.11K / 868.66K
- Beta
- —
- Shares outstanding
- 147.37M
52-week range
IFRX stock today
Shares of InflaRx N.V. (IFRX) finished lower on Nov 20 at $1.04, a drop of 4.59% or $0.05 per share, versus the S&P 500's 3.70% decline. Shares are 64.7% below their 52-week high of $2.95, set on May 7, 2026 and 30.3% above the 52-week low of $0.798, near the bottom of the past year's range. IFRX is up 3.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 11.9%.
InflaRx N.V. has posted a net loss over the last twelve months (EPS of -$0.37), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About InflaRx N.V.
Company profileInflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Prof. Niels C. Riedemann M.D., Ph.D.
- Headquarters
- Jena
- Employees
- 65
- IPO year
- 2017
- Website
- inflarx.de
Analyst forecast
ForecastConsensus (8 analysts)
none
Avg. price target
$8.28+696.15%
- Strong buy 1
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $-0.02 vs $-0.07
- Surprise
- +71.43%
IFRX news
All IFRX news- InflaRx Publishes First-In-Human Phase 1 Results For Izicopan; Stock UpNasdaqIFRX, LEN.B
- InflaRx N.V. Announces Publication of Phase 1 Data for IzicopanNasdaq
- InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of IzicopanGlobeNewswire
- InflaRx N.V. Reports €18.7 million Net Loss for the Nine Months Ended September 30, 2026Nasdaq
- InflaRx Announces November Investor EventsGlobeNewswire
- InflaRx N.V. Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026Nasdaq
- InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026GlobeNewswire
InflaRx N.V. peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ORMPOramed Pharmaceuticals Inc. | 3.57 | -3.25% | $155.24M | vs IFRX |
| ELDNEledon Pharmaceuticals Inc. | 1.78 | -6.32% | $150.34M | vs IFRX |
| RNAAtrium Therapeutics Inc. | 6.92 | -0.86% | $149.27M | vs IFRX |
| VRXAVeraxa Biotech AG | 1.04 | +0.97% | $147.06M | vs IFRX |
| PRQRProQR Therapeutics N.V. | 1.04 | -0.95% | $146.98M | vs IFRX |
| BBOTBridgeBio Oncology Therapeutics Inc. | 1.81 | -2.69% | $145.25M | vs IFRX |
| EMISEmmis Acquisition Corp. Class A | 10.36 | +0.15% | $163.36M | vs IFRX |
| ABEOAbeona Therapeutics Inc. | 2.42 | -1.22% | $165.31M | vs IFRX |
Indexes, lists and sector
InflaRx N.V. stock FAQ
What is InflaRx N.V.'s stock price today?
IFRX last traded at $1.04 as of Nov 20, 4:00 PM EST, down 4.59% on the day. Prices are delayed at least 15 minutes.
Who is InflaRx N.V.'s CEO?
Prof. Niels C. Riedemann M.D., Ph.D. is the chief executive officer of InflaRx N.V., which has about 65 employees.
What is the IFRX 52-week high?
The 52-week high for IFRX is $2.95 and the 52-week low is $0.798. The stock is currently 64.7% below its high.